Accustem Sciences Inc. (ACUT): Total Assets

Annual figures by period end, from SEC filings.

$1.55M
As of 2025-12-31
$1.61M
As of 2026-06-30
+18.1%
3-year compound annual growth
2021-12-31: $1.35M2022-12-31: $939.7K2023-12-31: $133.9K2024-12-31: $50.9K2025-12-31: $1.55M$1.55M
2021-12-31 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$1.55Mn/m2026-04-14, Balance as of period end
2024-12-31$50.9K-62.0%2026-04-14, Balance as of period end
2023-12-31$133.9K-85.8%2025-04-03, Balance as of period end
2022-12-31$939.7K-30.6%2024-03-22, Balance as of period end
2021-12-31$1.35Mn/a2023-02-15, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
Accustem Sciences Inc. (ACUT)2025-12-31$1.55Mn/m
Semnur Pharmaceuticals, Inc. (SMNR)2025-12-31$1.35M-79.9%
Aspire Biopharma Holdings, Inc. (ASBP)2025-12-31$1.31M+786.7%
Alzamend Neuro, Inc. (ALZN)2026-04-30$2.08M-54.8%
NeuroSense Therapeutics Ltd. (NRSN)2025-12-31$1.03M-77.5%
Inhibitor Therapeutics, Inc. (INTI)2025-12-31$2.51M-55.9%
Vaccinex, Inc. (VCNX)2024-12-31$2.60M-28.5%
Ocean Biomedical, Inc. (OCEA)2024-12-31$902.0K-83.6%
Lipella Pharmaceuticals Inc. (LIPO)2024-12-31$2.67M-25.3%

Compare ACUT, SMNR, ASBP, ALZN side by side · Screen every company in Pharmaceutical Preparations ↗